Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor
Monica Verdoia, Matteo Nardin, Rocco Gioscia, Federica Negro, Marco Marcolongo, Harry Suryapranata, Elvin Kedhi, Giuseppe De Luca
Topics & Concepts
MedicineTicagrelorAcute coronary syndromeInternal medicineCardiologyNeutrophil to lymphocyte ratioMean platelet volumeRevascularizationPercutaneous coronary interventionP2Y12PlateletLymphocyteMyocardial infarctionInflammatory Biomarkers in Disease PrognosisAntiplatelet Therapy and Cardiovascular DiseasesPlatelet Disorders and Treatments